Loading quotes...
Forecast
The analysts' average price target is €14.15 (+24.67%). The median is €12.53 (+10.40%).
| Buy |
12 |
| Hold |
12 |
| Sell |
4 |
News Go to news feed
Integra LifeSciences: operational recovery accelerating, margin and cash improvement expected
At the Wells Fargo Healthcare Conference, Integra LifeSciences reported continued recovery from supply-chain and quality issues: production capacity in Braintree has been ramped up and product relaunches such as PriMatrix, Durepair and SurgiMend are on schedule. The company reaffirmed its organic 2026 growth guidance of 0.8–3.3%, expects roughly a 100 basis-point expansion in EBITDA margin and about $150 million in free cash flow for 2026. Sales focus is shifting from supply management to clinical consulting, new products like Liberties (neurosurgery) are planned for 2027, and M&A will remain secondary until the balance sheet is stabilized. » More on de.investing.com
Integra LifeSciences under upward pressure after Argus upgrade
The stock of Integra LifeSciences rose 1.9% pre-market after Argus upgraded its rating from 'hold' to 'buy' and set a $25 price target. Argus cited restored confidence in management, resolved production bottlenecks and more stable revenue growth as reasons. Integra also beat Q1 results and raised its full-year guidance; risks remain product recalls and high debt. » More on de.investing.com
Integra LifeSciences reaches 52-week high at $16.49
Integra LifeSciences stock rose to a 52-week high of $16.49, 85% above its yearly low of $8.70; year-to-date return is 22.3%. InvestingPro points to an overbought RSI but still considers the stock undervalued relative to its fair value. The company beat expectations in Q1 2026 with adjusted EPS of $0.54 (expectation $0.40) and revenue of $392 million (expectation $381.81 million). » More on de.investing.com
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 363.01M | 5.96% |
| Gross profit | 185.28M | 3.84% |
| Net profit | 13.11M | 384.74% |
| EBITDA | 34.1M | 26.47% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €834.9M |
Number of shares | 77.77M |
52-week high/low | €18.35 - €7.79 |
| Dividends | No |
Beta | 1.21 |
P/E ratio | 71.45 |
PEG ratio | 0.11 |
P/B ratio | 0.88 |
P/S ratio | 0.56 |
Company profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
| Name | Integra Lifescience. |
| CEO | Stuart Essig |
| Headquarters | Princeton,
nj USA |
| Website | |
| Sector | Consumer Discretionary |
| Industry | Household Durables |
| IPO | 08/16/1995 |
| Employees | 4,427 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | IART |
Frankfurt | IL3.F |
Düsseldorf | IL3.DU |
SIX | IL3.SW |
München | IL3.MU |